- Home
- LNT vs UTHR Comparison
LNT vs UTHR Comparison
Compare LNT & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNT
- UTHR
- Stock Information
- Founded
- LNT 1917
- UTHR 1996
- Country
- LNT United States
- UTHR United States
- Employees
- LNT N/A
- UTHR N/A
- Industry
- LNT Power Generation
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- LNT Utilities
- UTHR Health Care
- Exchange
- LNT Nasdaq
- UTHR Nasdaq
- Market Cap
- LNT 14.8B
- UTHR 15.5B
- IPO Year
- LNT N/A
- UTHR 1999
- Fundamental
- Price
- LNT $63.46
- UTHR $372.89
- Analyst Decision
- LNT Buy
- UTHR Buy
- Analyst Count
- LNT 7
- UTHR 14
- Target Price
- LNT $62.50
- UTHR $370.86
- AVG Volume (30 Days)
- LNT 2.1M
- UTHR 364.3K
- Earning Date
- LNT 10-31-2024
- UTHR 10-30-2024
- Dividend Yield
- LNT 3.02%
- UTHR N/A
- EPS Growth
- LNT N/A
- UTHR 25.10
- EPS
- LNT 2.57
- UTHR 22.72
- Revenue
- LNT $3,966,000,000.00
- UTHR $2,756,200,000.00
- Revenue This Year
- LNT $5.29
- UTHR $26.32
- Revenue Next Year
- LNT $2.85
- UTHR $10.37
- P/E Ratio
- LNT $24.70
- UTHR $16.41
- Revenue Growth
- LNT N/A
- UTHR 25.04
- 52 Week Low
- LNT $46.80
- UTHR $208.62
- 52 Week High
- LNT $63.62
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- LNT 65.20
- UTHR 50.17
- Support Level
- LNT $59.40
- UTHR $353.65
- Resistance Level
- LNT $60.53
- UTHR $417.82
- Average True Range (ATR)
- LNT 1.24
- UTHR 11.15
- MACD
- LNT 0.50
- UTHR -3.43
- Stochastic Oscillator
- LNT 99.03
- UTHR 29.98
About LNT Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electric customers and 425,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
About UTHR United Therapeutics Corporation
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.